|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2012-03-13 |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
靶点- |
作用机制- |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Multi-center, Randomized, Double-blind, Active-controlled, Parallel-designed, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of PK101 Compared With PK101-002 in Patients With Knee Osteoarthritis
The purpose of this study is to compare the efficacy and the safety of PK101 in patients with knee osteoarthritis.
A Randomized, Open-label, Single Dose, 2x2 Crossover Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics After Administration of Fixed-dose Combination or Loose Combination of PK101 in Healthy Volunteers
The purpose of this study is to compare the safety and pharmacokinetics of PK101(fixed-dose combination of PK101-001 and PK101-002) with coadministration of the two separate drugs in healthy volunteers.
A Randomized, Open Labeled, Multiple Dose, 2-Sequence, 2-Period Cross-over Phase 1 Study to Evaluate the Drug-Drug Interaction of PK101-001 and PK101-002 in Healthy Volunteers.
To evaluate the drug-drug interaction of PK101-001 and PK101-002 in healthy volunteers.
100 项与 Pionex Management Group Pharm Co., Ltd. 相关的临床结果
0 项与 Pionex Management Group Pharm Co., Ltd. 相关的专利(医药)
100 项与 Pionex Management Group Pharm Co., Ltd. 相关的药物交易
100 项与 Pionex Management Group Pharm Co., Ltd. 相关的转化医学